Steven Cohen's CRL Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 221,592 shares of Charles River Laboratories International, Inc. (CRL) worth $44.2 M, representing 0.05% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CRL, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 307,600 shares. Largest reduction occurred in Q1 2024, reducing 368,984 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +221,592 | New Buy | 221,592 | $199.48 |
| Q3 2025 | -236,408 | Sold Out | 0 | $0.00 |
| Q2 2025 | +236,408 | New Buy | 236,408 | $151.73 |
| Q1 2024 | -368,984 | Sold Out | 0 | $0.00 |
| Q4 2023 | +307,398 | Add 499.14% | 368,984 | $236.40 |
| Q3 2023 | -193,592 | Reduce 75.87% | 61,586 | $195.98 |
| Q2 2023 | +255,178 | New Buy | 255,178 | $210.25 |
| Q4 2022 | -211,900 | Sold Out | 0 | $0.00 |
| Q3 2022 | +197,387 | Add 1360.07% | 211,900 | $196.80 |
| Q2 2022 | -64,148 | Reduce 81.55% | 14,513 | $213.95 |
| Q1 2022 | +1,761 | Add 2.29% | 78,661 | $283.97 |
| Q4 2021 | +64,006 | Add 496.40% | 76,900 | $376.78 |
| Q3 2021 | -32,587 | Reduce 71.65% | 12,894 | $412.67 |
| Q2 2021 | -108,541 | Reduce 70.47% | 45,481 | $369.91 |
| Q1 2021 | +83,770 | Add 119.24% | 154,022 | $289.83 |
| Q4 2020 | +16,780 | Add 31.38% | 70,252 | $249.86 |
| Q3 2020 | +53,472 | New Buy | 53,472 | $226.45 |
| Q2 2020 | -260,500 | Sold Out | 0 | $0.00 |
| Q1 2020 | +103,628 | Add 66.06% | 260,500 | $126.21 |
| Q4 2019 | +144,949 | Add 1215.71% | 156,872 | $152.76 |
| Q3 2019 | +11,423 | Add 2284.60% | 11,923 | $132.35 |
| Q2 2019 | +500 | New Buy | 500 | $142.00 |
| Q1 2019 | -307,600 | Sold Out | 0 | $0.00 |
| Q4 2018 | +307,600 | New Buy | 307,600 | $113.18 |
| Q2 2016 | -104,600 | Sold Out | 0 | $0.00 |
| Q1 2016 | -24,900 | Reduce 19.23% | 104,600 | $75.94 |
| Q4 2015 | +129,500 | New Buy | 129,500 | $80.39 |
| Q3 2015 | -185,000 | Sold Out | 0 | $0.00 |
| Q2 2015 | +185,000 | New Buy | 185,000 | $70.34 |
| Q1 2015 | -25,700 | Sold Out | 0 | $0.00 |
| Q4 2014 | -105,700 | Reduce 80.44% | 25,700 | $63.66 |
| Q3 2014 | +131,400 | New Buy | 131,400 | $59.74 |
Steven Cohen's Charles River Laboratories International Investment FAQs
Steven Cohen first purchased Charles River Laboratories International, Inc. (CRL) in Q3 2014, acquiring 131,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Charles River Laboratories International, Inc. (CRL) for 32 quarters since Q3 2014.
Steven Cohen's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q4 2018, adding 307,600 shares worth $34.81 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 221,592 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $44.2 M.
As of the Q4 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Charles River Laboratories International, Inc. (CRL) was 368,984 shares, as reported at the end of Q4 2023.